Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.48 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.48 |
| ▸ | BRD1 | O95696 | 1/20 | 0.48 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | PKLR | P30613 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.43 |
| ▸ | WNT3A | P56704 | 4/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL692531 | 0.90 | PKM (0.58) | PKMMAPTKEAP1NFE2L2DYRK1A | |
| SCHEMBL19692944 | 0.87 | USP9X (0.45) | PKMMAPTKEAP1NFE2L2TRIM24 | |
| SCHEMBL5984006 | 0.85 | PKM (0.55) | PKMMAPTKEAP1NFE2L2DYRK1A | |
| SCHEMBL6674134 | 0.83 | CA2 (0.59) | PKMMAPTKEAP1NFE2L2TRIM24 | |
| SCHEMBL6307961 | 0.83 | KEAP1 (0.51) | PKMMAPTKEAP1NFE2L2TRIM24 | |
| SCHEMBL12596097 | 0.83 | TRIM24 (0.51) | PKMMAPTKEAP1NFE2L2TRIM24 | |
| SCHEMBL1020435 | 0.81 | FFAR4 (0.54) | PKMMAPTPKLR | |
| SCHEMBL3776295 | 0.80 | KEAP1 (0.54) | PKMMAPTKEAP1NFE2L2TRIM24 | |
| SCHEMBL706682 | 0.77 | PKM (0.61) | PKMMAPTPKLR | |
| SCHEMBL9412823 | 0.77 | PKM (0.46) | PKMMAPTKEAP1NFE2L2PKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692094-A1 | SULFONAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Beijing Konruns Pharmaceutical Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-20230303552-A1 | ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS | VANDERBILT UNIVERSITY | 2023-09-28 | — | — | US | disclosed |
| US-20230303552-A1 | ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS | VANDERBILT UNIVERSITY | 2023-09-28 | — | — | US | disclosed |
| WO-2023150525-A1 | COMPETITIVE AND NONCOMPETITIVE PIPERIDINE SULFONYL INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150526-A1 | COMPETITIVE AND NONCOMPETITIVE OCTAHYDROCYCLOPENTA[C]PYRROLE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-11560386-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-3464292-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | disclosed |
| EP-3464292-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017214002-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017209155-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2017-12-07 | — | — | WO | disclosed |
| US-20170298016-A1 | PYRROLIC AMIDE COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | HITGEN INC. (CN) | 2017-10-19 | — | — | US | disclosed |
| US-8354548-B2 | Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354548-B2 | Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110207772-A1 | Glycine Chroman-6-Sulfonamides for Use as Inhibitors of Diacylglycerol Lipase | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-25 | — | — | US | disclosed |
| US-20110207772-A1 | Glycine Chroman-6-Sulfonamides for Use as Inhibitors of Diacylglycerol Lipase | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-25 | — | — | US | disclosed |
| EP-1735280-A1 | ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS | Kalypsys, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005115983-A1 | ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS | KALYPSYS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298016-A1 | PYRROLIC AMIDE COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | HDAC1, HDAC3, HDAC11 | PKM 866/4885MAPT 3879/4885KEAP1 2431/4885 |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | PKM 1092/4885MAPT 2286/4885KEAP1 2451/4885 |
| US-20230303552-A1 | ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS | CHRM5, CHRM1, CHRM2 | PKM 845/4885MAPT 2319/4885KEAP1 2063/4885 |
| US-20110207772-A1 | Glycine Chroman-6-Sulfonamides for Use as Inhibitors of Diacylglycerol Lipase | DAGLB, DAGLA, MGLL | PKM 3844/4885MAPT 4857/4885KEAP1 2888/4885 |
| US-11560386-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ADRB3, ADRB1, ADRB2 | PKM 3124/4885MAPT 4632/4885KEAP1 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.